Prognostic Significance of Amplification of the c-MYC Gene in Surgically Treated Stage IB-IIB Cervical Cancer
±èÅÂÁ¤, À̾ƿø, À̼ºÁ¾, ÀÌ¿øö, ÃÖ¿µÁø, À̱³¿µ, °Ã¢¼®,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÅÂÁ¤ ( Kim Tae-Jung )
Catholic University College of Medicine Department of Hospital Pathology
À̾ƿø ( Lee Ah-Won )
Catholic University College of Medicine Department of Hospital Pathology
À̼ºÁ¾ ( Lee Sung-Jong )
Catholic University College of Medicine Department of Obstetrics and Gynecology
ÀÌ¿øö ( Lee Won-Chul )
Catholic University College of Medicine Department of Preventive Medicine
ÃÖ¿µÁø ( Choi Yeong-Jin )
Catholic University College of Medicine Department of Hospital Pathology
À̱³¿µ ( Lee Kyo-Young )
Catholic University College of Medicine Department of Hospital Pathology
°Ã¢¼® ( Kang Chang-Suk )
Catholic University College of Medicine Department of Hospital Pathology
KMID : 0357920110450060596
Abstract
Background : Mutations of c-MYC have been described in cervical cancer. However, association between c-MYC gene status and its prognostic significance have not been clarified.
Methods : Tissue microarray sections from 144 patients with stage IB-IIB cervical cancer treated by radical hysterectomy were analyzed by fluorescence in situ hybridization using a region-specific probe for c-MYC and a centromere-specific probe for chromosome 8.
Results : Seventy five percent (108/144) of c-MYC gain and 6.9% (10/144) of c-MYC gene amplification were observed. c-MYC gene alteration was more frequently observed in squamous cell carcinoma than adenocarcinoma or adenosquamous carcinoma and were associated with low Ki67 labeling index (p=0.013). c-MYC amplification was not associated with clinicopathologic parameters except absence of bcl2 expression (p=0.048). Survival analysis revealed that patients with c-MYC amplification were significantly associated with higher risk of disease recurrence (p=0.007) and cancer related death (p=0.020). However, c-MYC gain was not associated with unfavorable outcome. Multivariate analysis proved c-MYC amplification as independent prognostic factors of shorter disease free survival and cancer-related death (p=0.028 and p=0.025, respectively).
Conclusions : c-MYC amplification, not gain, is an independent prognostic marker for shorter disease free and cancer specific survival in cervical cancer treated by radical hysterectomy.
Å°¿öµå
Uterine cervical neoplasms; In situ hybridization; fluorescence; MYC; Hysterectomy; Prognosis
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸